Brivaracetam Film-coated tablet + Brivaracetam oral solution

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Childhood Absence Epilepsy

Conditions

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

Trial Timeline

Mar 30, 2022 → Mar 18, 2025

About Brivaracetam Film-coated tablet + Brivaracetam oral solution

Brivaracetam Film-coated tablet + Brivaracetam oral solution is a phase 3 stage product being developed by UCB for Childhood Absence Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT05109234. Target conditions include Childhood Absence Epilepsy, Juvenile Absence Epilepsy.

What happened to similar drugs?

1 of 4 similar drugs in Childhood Absence Epilepsy were approved

Approved (1) Terminated (0) Active (3)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06315322Phase 3Recruiting
NCT05109234Phase 3Completed